1007346-42-0

Usage

Chemical structure

A complex structure containing a piperidin-2-one ring, a phenyl group, and a boron-containing dioxaborolan-2-yl group.

Boron coordination

The boron in the compound is part of a unique coordination and is present in a dioxaborolane ring system.

Potential applications

The compound may have potential applications in the field of organic chemistry and material science due to the presence of the boron-containing group.

Reactivity

The boron-containing group can exhibit unique reactivity and coordination chemistry, making it an interesting compound for further research and study.

Complex structure

The compound's complex structure and potential reactivity make it a valuable subject for further investigation in the fields of chemistry and material science.

Upstream product

• 4509-90-4 5-bromovaleroyl chloride 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1007346-47-5 3-{3-methyl-6-[4-(2-oxopiperidin-1-yl)phenyl]indazol-1-yl}benzonitrile 
• 1374263-59-8 tert-butyl [1-(4-{2-[4-(2-oxopiperidin-1-yl)phenyl]-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-3-yl}phenyl)cyclobutyl]carbamate 

Relevant academic research and scientific papers

MAP4K4 INHIBITORS

This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, f

Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds

The present invention relates to substituted benzo-imidazo-pyrido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-imidazo-pyrido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

7-Fluoroindazoles as potent and selective inhibitors of factor Xa

We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa inhibitors. The structure of a factor Xa cocrystal containing 7-fluoroindazole 51a showed the 7-fluoro atom hydrogen-bonding with the N-H of Gly216 (2.9 ?) in the peptide backbone. Thus, the 7-fluoroindazolyl moiety not only occupied the same space as the carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond interaction with the protein's β-sheet domain. The structure-activity relationship for this series was consistent with this finding, as the factor Xa inhibitory potencies were about 60-fold greater (ΔΔG ≈ 2.4 kcal/mol) for the 7-fluoroindazoles 25a and 25c versus the corresponding indazoles 25b and 25d. Highly convergent synthesis of these factor Xa inhibitors is also described.